C-N1UJthymus regeneration, immune monitoring, epigenetic clocks
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Continue or extend Intervene Immune's thymus regeneration and human longevity clinical research program.
Clinical trial referenced by Intervene Immune and listed on ClinicalTrials.gov; specific intervention details are not provided in the supplied material.
Listed by Intervene Immune as a pipeline program and referenced as TRIIM-X on ClinicalTrials.gov.
Evaluate a personalized and adaptive combination regimen for thymus regeneration, immunosenescence reversal, epigenetic aging biomarkers, and risk factors related to frailty, cancer, cardiovascular disease, diabetes, dementia, flu, and COVID-19.
Expanded pilot clinical study using personalized doses of recombinant human growth hormone somatropin, metformin, DHEA, additional agents, biomarker monitoring, and control groups to test biomarker variability and medication contributions.
ClinicalTrials.gov record for the Thymus Regeneration, Immunorestoration, and Insulin Mitigation Extension Trial was published on 2020-11-23.
Demonstrate thymus regeneration, immune rejuvenation, and potential epigenetic age reversal in humans.
Clinical study using a protocol intended to regenerate the thymus, with epigenetic clock measurements and immunological/risk-index assessments.
Peer-reviewed trial results published in 2019 reporting thymus-regeneration-related outcomes and epigenetic age reversal signals.
Reported protective immunological changes, improved risk indices for many age-related diseases, and mean epigenetic age approximately 1.5 years less than baseline after 1 year of treatment, with a -2.5-year change versus no treatment at the end of the study.